OXFORD, UK; 14 July 2026 – CaniVax™ Limited, the leader in developing novel therapeutics to treat canine cancer, has today announced the appointment of Dr Thu Nguyen to lead its canine cancer vaccine programme.
Dr Nguyen is a highly experienced cancer scientist with expertise at the intersection of cancer biology, immunology, and tumour antigen discovery. As Principal Scientist at CaniVax™, Dr Nguyen will lead the company’s cancer vaccine programme, translating advances in tumour immunology into novel clinical therapies. Dr Nguyen received the highly competitive Vingroup Scholarship before earning a DPhil in Oncology from the University of Oxford, and since has developed extensive expertise in developing novel therapeutics to enhance immune recognition of cancer.
James Noble, Chair of CaniVax™, commented:
“We are delighted to welcome Dr Nguyen to CaniVax™. Our pipeline of advancing therapeutic assets will respond favourably to the new expertise and help enormously in translation into clinical studies and returning shareholder value.”
Dr Nguyen commented:
“It is an honour to take on the role of Principal Scientist at CaniVax™ and to lead the company’s cancer vaccine development programme. Cancer remains one of the greatest health challenges facing our canine companions, and advancing innovative immunotherapies that improve therapeutic outcomes and quality of life for dogs with cancer is a major objective.”
NOTES:
About CaniVax™ Limited
CaniVax™ is an Oxford based veterinary biotechnology company focused on applying advances in cancer immunology and vaccination to dog cancers. The company brings together expertise in cancer biology, translational science, and veterinary oncology to address cancers where existing treatment options remain limited. The company’s platforms and expertise are derived from leading research institutes, universities and biopharma companies. The company is ideally positioned to realise its mission of bringing new cancer vaccines to the forefront of canine therapy. The company works in collaboration with academic and translational researchers, veterinary professionals and commercial teams, recognising that meaningful progress requires close alignment between scientific discovery, clinical reality and commercial acumen.
Download the Press Release here
For further information contact:
www.canivax.com
See: CaniVax LinkedIn